Table 4.

Receiver operating characteristics of the informative sets for bladder cancer detection

No.GenesTP/FNFP/TNSensitivity (%), TP / (TP + FN)Specificity (%), TN / (TN + FP)Statistical significance
1SALL377/550/2358.3100.03.551E−08
2SALL3, CFTR98/340/2374.2100.03.205E−12
3SALL3, CFTR, ABCC6106/260/2380.3100.03.522E−14
4SALL3, CFTR, ABCC6, HPP1109/230/2382.6100.04.970E−15
5SALL3, CFTR, ABCC6, HPP1, RASSF1A113/192/2185.691.35.274E−13
6SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A114/183/2086.487.05.392E−12
(6)SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A (RUNX3)114/183/2086.487.05.392E−12
(6)SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A (RUNX3, ITGA4)114/183/2086.487.05.392E−12
(6)SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A (RUNX3, ITGA4, BCL2)114/183/2086.487.05.392E−12
7SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4115/173/2087.187.02.617E−12
(7)SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4 (MYOD1)115/173/2087.187.02.617E−12
(7)SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4 (MYOD1.DRM)115/173/2087.187.02.617E−12
8SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4, CDH13117/153/2088.687.05.607E−13
(8)SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4, CDH13 (BMP3B)117/153/2088.687.05.607E−13
(8)SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4, CDH13 (BMP3B,CCNA1)117/153/2088.687.05.607E−13
9SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4, CDH13, RPRM119/133/2090.287.01.037E−13
10SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4, CDH13, RPRM, MINT1120/123/2090.987.04.184E−14
11SALL3, CFTR, ABCC6, HPP1, RASSF1A, MT1A, ALX4, CDH13, RPRM, MINT1, BRCA1121/113/2091.787.01.606E−14
Bladder cancer (123)Nontumor control (23)
MethylatedTP (121)FP (3)
UnmethylatedFN (11)TP (20)
  • NOTE: The first column is the list of each gene sets. The gene in brackets was considered redundant as its inclusion did not improve the sensitivity. The second is the true positive (the bladder cancer case having at least one gene methylated) and false negative (the bladder cancer case having no gene methylated) events in the bladder cancer cohort. The third is the false positive (the noncancerous urinary lesion case having at least one gene methylated) and true negative (the noncancerous urinary lesion case having no gene methylated) events in the noncancerous urinary lesion cohort. The fourth is sensitivity in percentage derived from the equation [TP/(TP+FN)]. The fifth is specificity in percentage from the equation (TN+FP).

    Abbreviations: TP, true positive; FN, false negative; FP, false positive; TN, true negative.